Introducing Vernakalant into Clinical Practice-Reference-Cited by-同舟云学术

Introducing Vernakalant into Clinical Practice

Published:2019-03-12 Issue:1 Volume:8 Page:70-74
ISSN:2050-3369
Container-title:Arrhythmia & Electrophysiology Review
language:en
Short-container-title:Arrhythm Electrophysiol Rev

Author:

Hall Angela JM¹,Mitchell Andrew RJ¹

Affiliation:

1. Department of Cardiology, Jersey General Hospital, Jersey, Channel Islands

Abstract

Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilitating early discharge from hospital in selected patients in place of electrical cardioversion. The authors explore the data behind vernakalant and discuss how it can be introduced into clinical practice.

Publisher

Radcliffe Group Ltd

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study;AS;JAMA,2001

2. Atrial fibrillation;Lip;Lancet,2012

3. Increasing prevalence of atrial fibrillation and flutter in the United States;Naccarelli;Am J Cardiol,2009

4. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060;Krijthe;Eur Heart J,2013

5. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS;Kirchoff;Eur Heart J,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

2. External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-06-03

3. Efficacy and Safety of Intravenous Vernakalant in Rapid Cardioversion of Recent Onset Atrial Fibrillation: A Retrospective Single-Centre Study;Cureus;2024-04-19

4. The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department;Medicina;2023-12-02

5. Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients;International Journal of Molecular Sciences;2023-08-16